Vasculitis & polymyalgia rheumatica
Effectiveness of intravenous infliximab versus subcutaneous adalimumab in Takayasu arteritis: multicenter retrospective study
Authors' conclusion
In this study, we confirm that IFX and ADA are both effective in TAK, without significant differences in the risk of relapse and revascularizations.
Study context
- Population
- Patients with TAK at referral centres in France, Italy, Spain, Armenia, Israel, Japan, Tunisia and Russia, January 2017 to September 2019
- Participants
- 135 patients
- Exposure
- Intravenous infliximab vs subcutaneous adalimumab
- Infliximab (IFX)n = 101
- ADAn = 34reference
- Outcome
- Complete response (NIH <2 with <7.5 mg/day prednisone)
- Follow-up
- 6 months
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
P = 0.8
- Overall complete response
- 71%
Observational data: associations, not effects.
Further findings
| Outcome | IFX | ADA |
|---|---|---|
| Risk of relapse · 12 months | 10.9% (interval 0–21.9) | 16.8% (interval 8.64–24.27) |
- Risk of relapse: median [IQR] follow-up 23 [17, 42] months IFX and 48 [25, 99] months ADA
Cumulative incidence of treatment failure
- Not significantly different between IFX and ADA
Overall incidence of revascularizations
- Not significantly different
Factors associated with complete response to TNF-α inhibitors at 6 months (univariate analysis)
- Age <30 years, tobacco use, vascular signs at biologic initiation, NIH ≥2, CRP >20 mg/l, starting prednisone dose >20 mg/day; not the use of either IFX or ADA
Original publication
Effectiveness of intravenous infliximab versus subcutaneous adalimumab in Takayasu arteritis: multicenter retrospective study. Rheumatology (Oxford). Published 14 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →